GlassScriptPhysician profile
Ralph Dunnigan
NPI 1932151586
$1,830.65
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.91 · 2021: $1,608 · 2022: $190.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,440.90 | 2021-2022 | |
| Abbvie INC. | $239.25 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $22.03 | 2022 | |
| Allergan, INC. | $18.55 | 2021 | |
| Pfizer INC. | $18.43 | 2019 | |
| Acadia Pharmaceuticals INC | $16.98 | 2022 | |
| Novo Nordisk INC | $16.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.52 | 2022 | |
| Biogen, INC. | $14.48 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.21 | 2022 | |
| Acorda Therapeutics, INC | $14.11 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Dunnigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.